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Abstract
Background: A large number of epigenetic alterations has been found to be implicated in the etiology of
gastric cancer. We have studied the DNA methylation status of 27 500 gene promoter regions in 24 gastric
adenocarcinomas from a Norwegian cohort, and aimed at identifying the hypermethylated regions. We have
compared our findings to the gene expression in the same tissue, and linked our results to prognosis and survival.
Methods: Biopsies from gastric adenocarcinomas and adjacent normal gastric mucosa were obtained from 24
patients following surgical resection of the tumor. Genome-wide DNA methylation profiling of the tumor and
matched non-cancerous mucosa was performed. The results were compared to whole transcriptome cDNA
microarray analysis of the same material.
Results: Most of the gene promoter regions in both types of tissue showed a low degree of methylation, however
there was a small, but significant hypermethylation of the tumors. Hierarchical clustering showed separate grouping
of the tumor and normal tissue. Hypermethylation of the promoter region of the GFRA3 gene showed a strong
correlation to post-operative survival and several of the clinicopathological parameters, however no difference was
found between the two main histological types of gastric cancer. There was only a modest correlation between the
DNA methylation status and gene expression.
Conclusions: The different DNA methylation clusters of the tumors and normal tissue indicate that aberrant
DNA methylation is a distinct feature of gastric cancer, although there is little difference in the overall, and low,
methylation levels between the two tissue types. The GFRA3 promoter region showed marked hypermethylation in
almost all tumors, and its correlation with survival and other clinicopathological parameters may have important
prognostic significance.
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Background
Gastric cancer (GC) is second to lung cancer in world-
wide cancer-related deaths, and is the result of a com-
plex interplay between chronic Helicobacter pylori
infection, human genetic factors and environmental car-
cinogens. However, it is becoming increasingly clear that
cancer development is as much a result of epigenetic
alterations, as it is a genetic disease [1]. Genetic muta-
tions are relatively infrequent in GC, whereas epigenetic
alterations such as DNA methylation may be much more
important in promoting GC [2]. DNA methylation is an
heritable modification of gene activity, which does not
make alterations to the DNA sequence, but involves at-
tachment of a methyl group to the carbon 5 position of
cytosines, most commonly where cytosine occurs next
to guanine, separated by phosphate known as a CpG di-
nucleotide. Most focus has been directed at DNA hyper-
methylation, however whole genome hypomethylation is
prevalent in several cancers [3–5]. Hypermethylation of
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gene promoter regions may result in silencing of tumor
suppressor genes, however the role of hypomethylation
has been less clear, but may be associated with increased
expression of oncogenes [6]. A distinctive DNA methyla-
tion phenotype has been identified in colorectal cancer
(CIMP) [7], and particular methylation patterns have
been associated with subgroups of breast cancer [8],
lung cancer [9] and glioma [10]. A CIMP in gastric cancer
has been suggested, but is controversial [11]. Several
causes of aberrant DNA methylation in GC have been
established, including aging, dietary causes and microor-
ganisms such as H. pylori and Ebstein-Barr virus [12–16].
In a previous study we compared the gene expression
profile of 20 gastric tumors against matched non-
cancerous mucosa. We identified the most differentially
expressed genes and related these to postoperative sur-
vival [17]. Nine genes relevant to gastric carcinogenesis
had previously shown similar expression patterns in H.
pylori exposed gastric mucosa cells in vitro [18]. We
suggested that the increased expression of these genes in
the gastric tumors may represent early events in gastric
carcinogenesis mediated by chronic H. pylori infection,
in particular claudin-1 (CLDN1) and interleukin-8 (IL-8).
The aim of the present study was to examine the DNA
methylation status in gastric adenocarcinomas whose
gene expression were previously determined by cDNA
microarrays [17]. We aimed at assessing the overall state
of hypo- or hypermethylation in the tumors, and identify
whether there was an association between the DNA
methylation status, clinicopathological factors and gene
expression.
Methods
Tissue and patient characteristics
Patients with non-cardia gastric adenocarcinoma were
identified during upper endoscopy at the outpatient
clinic at Akershus University Hospital, Norway, with a
histopathological diagnosis of diffuse or intestinal type
GC. Thoraco-abdominal computed tomography imaging
was performed to exclude patients with distant meta-
static disease, ineligible for curative surgery. On admis-
sion for surgery, written, informed consent was obtained
from all participants in the study. Immediately following
the removal of the principal surgical specimen, two tis-
sue samples from each patient were obtained: one from
the tumor mass border and another from healthy gastric
corpal mucosa, at least 5 cm away from the tumor. The
samples were immediately fresh frozen on dry ice, before
definitive storage at −80 ° C. All sample acquisition and
handling were performed by the same individual. The
tumors were verified and further classified by two senior
specialist pathologists. The study was approved by the
Regional Ethics Committee (REK) and the ethics com-
mittee at Akershus University Hospital. All samples and
patient data were coded and blinded before analysis. Pa-
tients, clinicopathological characteristics, diagnostic are
presented in Table 1.
Methylation assays
Total DNA was extracted from the fresh frozen tissue
using Dneasy Blood and tissue kit (Qiagen GmBH,
Germany) according to the manufacturer’s standard
preparation protocol. DNA concentration and 260/280
ratio were then assessed using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, USA), and
found to be adequate for further analysis. 500 ng of
DNA was bisulphite converted using the EpiTect 96
Bisulfite Kit (Qiagen GmbH, Germany). Effective bisul-
phite conversion was verified by absolute quantification
assay using Applied Biosystem7900HT/7900HTFast Real
Time PCR System Amplification and pairs of primers
specific for either converted or unconverted DNA. An
aliquot of 4 μL of the bisulphite converted DNA was
used to perform genome-wide DNA methylation profil-
ing of 24 gastric tumors against matched non-cancerous
mucosa using the Illumina HumanMethylation27 Bead-
Chip. This platform detects the methylation status of 27
578 different CpG sites in >14 000 promoters in the hu-
man genome. The experiment was performed using the
Table 1 Patient characteristics and clinicopathological features
of the 24 gastric tumors used in the study
Number and sex of patients n = 24 (females n = 7,
males n = 17)
Ethnicity Caucasian n = 21 Asian n = 3
Age at surgery Total: 68.4 years (±12.3)
Females: 65.4 years (±21.5)





(alive individuals at study end)
46.0 months (±8.0)
Tumor size 47 mm (±28)








Histological type Intestinal 6
Diffuse 14
Mixed 4
Values are the mean plus/minus standard deviation where appropriate. The
details of gender associated with death and survival have been combined
Eftang et al. BMC Cancer  (2016) 16:225 Page 2 of 11
Infinium Methylation Assay Experienced User Card
protocol. All steps were performed according to the Infi-
nium protocol.
Immunohistochemistry
The presence of H. pylori in the surgical specimens was
analyzed using a polyclonal anti-Helicobacter-antibody
(Dako, Denmark, code B0471, dilution 1:200). 4 μm sec-
tions of formalin-fixed, paraffin-embedded tissue from
non-tumorous mucosa were applied on coated slides.
Deparaffinization, rehydration and epitope retrieval were
performed in a Dako PT Link (Dako, Denmark) at 97 °C
for 20 min. The immunostaining procedure was carried
out in a Dako Autostainer Plus applying the Envision™-
Flex, High pH system (Dako, Denmark).
Statistical analysis
Data was processed using the lumi R package. All probes
that contained a “zero” value in at least one sample for
methylated and unmethylated signals were removed from
further analysis. Intra-sample normalization consisted of
color bias correction, which is the normalization between
the two color channels, and background level correction,
using the negative control probes present on the array.
Lastly, quantile normalization was performed on the in-
tensities of methylated and unmethylated probes separ-
ately, instead of the summarized methylation levels. β-
values (the degree of methylation) were used for further
analysis. The β-value at each CpG site represents continu-
ous value from 0 to 1 where 0 is fully unmethylated and 1
is entirely methylated at that locus. The Δβ value is the
difference between the β value of the tumor sample and
that of the normal sample, ranging from −1 to 1.
The Δβ value was calculated for all CpG sites in all
sample pairs, and the data were loaded into the J-
express software package [19]. Rank product testing [20]
was then performed to test whether the differential
methylation between tumor tissue and matched normal
mucosa was significant. The Δβ value was declared sig-
nificant if the adjusted p-value, i.e. the FDR q-value, was
less than 0.05. Hierarchical clustering was performed
using utilizing the J-express software package [19].
The filtered dataset, consisting of the 200 most signifi-
cant Δβ values, was imported into Pathway Express, part
of the Onto-Tools software suite [21, 22], for KEGG
(Kyoto Encyclopedia of Genes and Genomes) cellular
signaling pathway analysis [23]. Pathway Express calcu-
lates an Impact Factor (IF), which is used to rank the af-
fected signaling pathways, based on the fold change, the
number of the involved genes in the pathway, and the
amount of perturbation of downstream genes [24].
The filtered dataset was then entered into SPSS Statis-
tics (IBM Software, New York, USA, version 22.0.0.1) to
perform correlation analysis to select differentially
methylated gene promoter regions that associated with
gene expression and clinicopathological parameters.
Both Pearson and Spearman correlation coefficients
were employed to identify associations. In the one CpG
site that was highly correlated to survival, different cut-
off levels were applied to construct high and low meth-
ylated groups, before statistical significance between
the groups was assessed using a log-rank (Mantel-Cox)
test. A Kaplan-Meier survival plot was created to dem-
onstrate the difference in survival between the high and
low expression groups. Linear regression analysis was
then performed, to predict determinants of CLDN1
expression, using Stata (StataCorp LP, Texas, USA,
version 13.1).
The DNA methylation data are available in the





To investigate the DNA methylation status of 24 GC
samples and matched controls, more than 27 500 gene
promoter sites were examined using the Illumina Infi-
nium HumanMethylation27K platform. First, the methy-
lation status of the entire dataset was considered. Most
CpG sites, including both the tumor and normal tissue,
demonstrated low levels of methylation, i.e. low β values.
Second, there was little variance between the samples
within each locus, even between the tumor and normal
groups. This is illustrated in the histogram in Fig. 1 and
in the colored heatmap in Fig. 2.
Then, the Δβ values for each CpG site were calculated.
53.1 % of all sites demonstrated a net positive value,
whereas 46.9 % demonstrated a net negative value, indi-
cating a slight overall increase in CpG methylation in
the tumors.
Rank product testing
Of the 27 500 CpG sites on the array, 1 660 CpG sites,
corresponding to 1 194 genes, showed statistically sig-
nificant increased methylation in the tumor relative to
normal mucosa, whereas 1 276 CpG sites, corresponding
to 1 017 genes, showed significant decreased methyla-
tion in the tumor relative to normal mucosa, supporting
the trend from the entire dataset.
The dataset of all significant CpG sites was then sub-
jected to hierarchical clustering using average linkage
and Euclidean distance measure, using the J-express
2012 software package [19]. There was a tendency for
the tumor samples to cluster together, and for the nor-
mal samples to cluster together, indicating stronger
methylation similarities within each of the two groups,
than within each of the sample pairs (Fig. 3).
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Filtering of statistical CpG sites
To produce a reasonably sized list of the most differen-
tially methylated CpG sites, a list of the 100 most hyper-
methylated and the 100 most hypomethylated CpG sites
in the tumor relative to the control were created, hereby
referred to as the filtered dataset (Additional file 1).
Clinicopathological correlation
The filtered dataset was then compared to post-operative
survival, tumor size, Lauren classification, lymph node
metastasis, gastric mucosa metaplasia and atrophy and H.
pylori, listed in Table 2.
Although 44 CpG sites showed relationship with one
or more of the factors, the promoter region of the
GFRA3 gene showed significant relationship with nearly
all the clinicopathological factors. Firstly, an inverse rela-
tionship was detected between the GFRA3 promoter Δβ
values and post-operative survival (p = 0.01). High and
low methylated GFRA3 groups were constructed using
the GFRA3 promoter Δβ mean (p = 0.017) as the group
divider, as demonstrated in the Kaplan-Meier survival
plot in Fig. 4. Secondly, a strong, and highly statistically
Fig. 1 Histogram of the Δβ values. The frequency of the Δβ values
in the dataset of >27 000 CpG sites shows that most CpG sites
demonstrated little variance between gastric tumor and normal tissue
Fig. 2 A heatmap presentation of the DNA methylation levels of the entire dataset of 27564 CpG sites in 24 tumor and normal gastric cancer tissue
pairs. A value of 0.00 (most green) indicates fully unmethylated, whereas a value of 1.00 (most red) indicates entirely methylated locus. The figure
demonstrates that the majority of CpG sites in the dataset, including both tumor and normal tissue, showed low levels of DNA methylation
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significant positive relationship was identified between
GFRA3 Δβ and gastric atrophy (p < 0.001). Thirdly, there
were statistically significant, although slightly weaker
positive correlations between GFRA3, Δβ and lymph
node metastasis (p = 0.028), the degree of gastric mucosa
metaplasia (0.044) and also patient age at surgery (p =
0.038). There was no association between the GFRA3
promoter methylation levels and histological subtype or
H. pylori status, nor did we find significant correlation
to GFRA3 gene expression extracted from our previous
publication [17].
A multivariable Cox regression was then performed.
Controlling for age at surgery, tumor size and histo-
logical type, GFRA3 methylation level was still a highly
significant (p = 0.01) predictor of survival.
Gene expression correlation
The filtered dataset was compared to corresponding
gene regulation, imported from our previous study [17],
to analyze whether the gene promoter methylation status
could account for aberrant gene expression. Of the 100
most hypermethylated CpG sites in the tumor relative to
the control, four CpG sites showed a statistically signifi-
cant inverse correlation with gene expression, listed in
Table 3. Among the 100 most hypomethylated CpGs, six
CpG sites showed significant inverse relationship with
gene expression (Table 4).
The 130 most differentially regulated genes in the
tumors [17] were then compared against DNA methyla-
tion (Table 5). Three genes showed an inverse relation-
ship with the methylation status of their gene promoter
region.
Then, to investigate the association between the most
significant genes from our previous study [17], and
GFRA3 gene methylation from the current study, linear
step-wise regression was performed. IL-8 gene expres-
sion (p = 0.006) and GFRA3 methylation (p = 0.008) were
highly associated with CLDN1 expression.
Cellular signaling pathways
Then the filtered dataset was analyzed for associated
KEGG signal pathways using Pathway Express. Signifi-
cantly impacted pathways and corresponding Impact
Factor (IF) are presented in Table 6. None of the hyper-
methylated CpG sites (in the tumor relative to normal)
associated with any KEGG pathways, while many of the
hypomethylated CpG sites significantly associated with
six cellular signaling pathways; including three cancer-
related pathways.
Assorted genes
Finally, the β and Δβ values for particular gene pro-
moter regions were noted: TIMP3, SEMA3B, FBP2,
TEAD4, CDH1, CDKN2A, LOX, MLH1, and SFRP1, 2
Fig. 3 Hierarchical clustering of the normal and tumor samples. Top row: Tumor samples are shaded grey, normal gastric tissue samples are
white. A value of 0.00 (most green) indicates fully unmethylated, whereas a value of 1.00 (most red) indicates entirely methylated locus. Most
normal tissue samples seem to concentrate on the left side of the heatmap, whereas most tumor samples aggregate on the right, indicating
similarities within the two groups
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Table 2 Associations between hypermethylated and hypomethylated CpG sites and clinicopathological features
Post-op survival Lymph node metastasis Tumor size Lauren classification Metaplasia Atrophy H. pylori
CpgID/Gene promoter
Hypermethylated in the tumor
cg09350274/GFRA3 r = −0.69 p = 0.002 r = 0.52 p = 0.028 r = 0.48 p = 0.42 r = 0.480 p = 0.044 r = −0.590 p = 0.01
cg02720618/ESR1 r = 0.56 p = 0.016
cg04623837/HCG9 r = 0.64 p = 0.004
cg07307078/TUBB6 r = 0.49 p = 0.04
cg08615333/TGFB3 r = 0.5 p = 0.037 r = 0.504 p = 0.033
cg01566170/CAPN2 r = −0.53 p = 0.023 r = 0.526 p = 0.025
cg16986846/SCGB2A1 r = −0.576 p = 0.012
cg02633817/FXYD3 r = −0.474 p = 0.047
cg20640433/LAMA2 r = 524 p = 0.026
cg21905630/GSH2 r = 0.52 p = 0.028
cg13718960/RNASE1 r = 0.554 p = 0.017
cg19118812/ELMO1 r = −0.546 p = 0.019
cg26557658/FAM43B r = −0.604 p = 0.008
cg03616357/FLJ21159 r = 0.574 p = 0.013
cg08615333/TGFB3 r = 0.504 p = 0.033
cg14189571/ZFP42 r = 0.484 p = 0.042
cg17872757/FLI1 r = 0.495 p = 0.037
cg21790626/ZNF154 r = 0.573 p = 0.013
cg27546237/COL4A1 r = 0.527 p = 0.025
CpgID/Gene promoter
Hypomethylated in the tumor
cg13694749/SCN4A r = −0.638 p = 0.004
cg18059088/HS3ST1 r = −0.474 p = 0.047
cg26619317/CNN3 r = 0.481 p = 0.043
cg07131544/NCR2 r = 0.496 p = 0.036
cg14696870/FCER1A r = −0.567 p = 0.014
cg20676475/LCE3D r = −0.708 p = 0.001
cg00974864/FCGR3B r = −562 p = 0.015
cg13180098/RHO r = −0.604 p = 0.008 r = −0.597 p = 0.009 r = 0.682 p = 0.002
cg24691453/S100A4 r = 0.470 p = 0.49











Table 2 Associations between hypermethylated and hypomethylated CpG sites and clinicopathological features (Continued)
cg26789453/TMEM116 r = −0.512 p = 0.030
cg26264314/NALP5 r = −0.474 p = 0.047
cg20383064/BFSP2 r = −0.487 p = 0.040
cg25119415/MNDA r = −0.646 p = 0.004 r = −0.514 p = 0.029 r = 0.547 p = 0.019
cg14603345/BTBD3 p = −0.483 r = 0.042
cg17356733/IFNGR2 r = −0.480 p = 0.044
cg23756272/BCL2 r = −0.500 p = 0.035
cg00842351/TJP2 r = −527 p = 0.24
cg25248094/SH2D1A r = 0.487 p = 0.041 r = −0.526 p = 0.025
cg04454050/TREML1 0.474 0.047
cg02611419/KCNK17 r = −502 p = 0.034
cg05252264/FCAR r = 0.587 p = 0.10
cg22268164/TRHR r = −0.619 p = 0.006
cg02046017/LOC220070 r = 0.475 p = 0.046
cg09191232/PAPSS1 r = −0.581 p = 0.011
The filtered list of 100 hypermethylated and 100 hypomethylated CpG sites were compared to associated gene expression. 19 of the hypermethylated CpG sites and 25 of the hypomethylated CpG sites showed















Although there is currently a major interest in the
relationship between DNA methylation and various hu-
man diseases, the significance of DNA methylation was
highlighted more than 30 years ago by Ehrlich et al. [25],
who showed that the extent of methylation varies signifi-
cantly across human tissues. However, gastric tissue was
not studied in detail. In this study we have characterized
the DNA methylation pattern in 24 GCs compared to
matched normal mucosa. Overall, both tumor and nor-
mal mucosa tissue demonstrated similar methylation
levels across the genome, where at least two thirds of
the 27 500 CpG sites showed a very low degree of
methylation. The tumor and normal tissues showed very
similar overall methylation patterns, however there was
a slight net increase in the global DNA methylation
levels in the tumor. This contrasts the belief that global
DNA hypomethylation is a general hallmark of all can-
cer. In concordance with other recent studies we found
increased DNA methylation in the tumors in the pro-
moter regions of TIMP3, SEMA3B, FBP2, CDH1,
CDKN2A, MLH1, and SFRP1,2 and 5 [19–22, 26–31].
Hierarchical clustering of the entire dataset illustrated
different methylation patterns between the tumor and
the control tissue, and this exercise may distinguish
tumor from adjacent tissue with relative accuracy. Statis-
tically significant subclustering between the histological
subtypes, according to the Lauren classification, was not
seen, probably because of the low sample size. However,
the aggregation of the intestinal tumor samples towards
Fig. 4 Kaplan Mayer survival plot of patients with resected gastric tumors. High and low methylated GFRA3 groups were constructed, using the
mean value as the group divider. Individuals with hypermethylation of the GFRA3 promoter region showed a highly unfavorable prognosis,
whereas individuals with a low degree of methylation at that locus demonstrated a relatively good prognosis
Table 3 Correlation between hypermethylated gene promoters





P value Spearman’s rho P-value
CPD NS −0.482 0.043
DEFB106A −0.531 0.23 −0.529 0.024
FCGR3B −0.575 0.13 −0.569 0.014
GATA4 NS −0.643 0.004
The 100 most significant hypermethylated gene promoter sites were
correlated with their respective gene expression. Only statistically significant
correlations are shown (p < 0.05)
Table 4 Correlation between hypomethylated gene promoters





P value Spearman’s rho P-value
DHX32 −0.495 0.037 −0.624 0.006
PPYR NS −0.490 0.039
FOXI1 −0.683 0.002 −0.511 0.03
ORM1 −0.594 0.009 −0.670 0.002
ZSCAN18 Ns −0.511 0.030
PXDN −0.480 0.44 −0.579 0.012
The 100 most significant hypomethylated gene promoter sites were correlated
to their respective gene expression. Only statistically significant correlations
are shown (p < 0.05)
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the right of the heat map in Fig. 3 may illustrate a separ-
ate methylation profile within this subtype, which could
be more prominent in a larger study. Different DNA
methylation profiles in the histological subtypes have
been suggested by Wang et al. who demonstrated global
hypomethylation intestinal type cancers, and gene pro-
moter hypermethylation in diffuse type cancers [23].
This paradox may explain why several other authors in
the past have reported both genome wide hypermethyla-
tion and hypomethylation in GC tissue.
Correlation with clinicopathological parameters and gene
expression
Further, we observed that DNA methylation of the
GFRA3 gene promoter showed significant correlation
with almost all clinicopathological parameters. Most im-
portantly, high methylation levels of GFRA3 conferred a
very unfavorable prognosis, with no high-expressing in-
dividuals surviving 20 months. GFRA3 codes for the
artemin receptor which mediates activation of the RET
proto-oncogene, and has been implicated in a GC diag-
nostic and prognostic signature [24]. In breast cancer,
increased expression of GFRA3 was associated with
lymph node metastasis and advanced tumor stage [32].
In pancreatic cancer GFRA3 may be implicated in the
promotion of the disease through increased cell motility
and invasiveness [33, 34], and this gene is also up regu-
lated in non-small cell lung cancer [35]. We expected to
see down regulation of the GFRA3 gene in the hyper-
methylated tumor specimens, however there was no
significant association between the GFRA3 methylation
levels and gene expression in the study. Furthermore, it
is widely accepted that there are distinct differences in
the tumor biology between diffuse and intestinal GC.
This difference, however, was not reflected in the GFRA3
promoter methylation levels, as we found no differences
in GFRA3 methylation levels between the two histo-
logical types. GFRA3 may play different roles in the two
cancer types, however a larger study is necessary to clar-
ify whether there exists a true difference between the
methylation of this gene in the two histological types
and its significance.
In our previous study [17], we found that CLDN1 gene
expression was highly associated with reduced post-
operative survival, and that IL-8 was the most highly up-
regulated gene in the tumor specimens. Although there
was no association between the methylation levels of
these genes and their expression, we wanted to investi-
gate the relationship between the most prominent find-
ings in our two studies: CLDN1 and IL-8 gene expression
and GFRA3 promotor methylation: Indeed, the expression
of CLDN1 was statistically associated with both the IL-8
gene expression and GFRA3 promotor methylation. The
association between GFRA3, IL-8 and CLDN1 and the
clinical features such as post-operative survival, lymph
node metastasis, gastric metaplasia and patient age may
describe a more complex relationship which we have not
further evaluated in this study.
Between the 200 most differentially methylated CpG
sites, and the 130 most differentially regulated genes,
there was a significant inverse relationship between
methylation and gene expression in 13 of the genes, con-
firming that DNA methylation may be one of several
regulatory mechanisms of gene expression in GC. How-
ever, other mechanisms than DNA methylation must
account for the majority of gene regulation, such as
gene mutations, and other epigenetic mechanisms like
histone modifications, nucleosome positioning, non-
coding RNAs, and microRNAs.
The cause of hypermethylation in gastric cancer is un-
clear, nonetheless infectious agents may be an important
contributing factor. There is a strong association be-
tween H. pylori and GC, recognized by the World
Health Organization as a class 1 carcinogen [36]. H. pyl-
ori triggers the chronic inflammatory process that results
in the mucosal transformation leading to GC, described
by Correa [37] and later refined by Tahara [38]. The role
of H. pylori in the methylation of gastric mucosal DNA,
however, has not been extensively studied. It has been
observed that cag+ H. pylori infection results in both
global hypomethylation in gastric mucosa [14–16] and
hypermethylation of promoter regions of several tumor
suppressor genes [39]. Chronic inflammation per se has
also been shown to cause aberrant methylation in gastric
Table 5 Correlation between the most differentially regulated





P value Spearman’s rho P-value
SPP1 ns −0.523 0.026
ALDH3A1 ns −0.560 0.016
TCN1 ns −0.521 0.027
The 130 most differentially regulated genes imported from our previous paper
[17] were compared to corresponding gene promoter methylation levels.
Significant correlations are shown (p < 0.05)
Table 6 KEGG cellular signaling pathways
Pathway name Impact factor p-value
Natural killer cell mediated cytotoxicity 6.7 0.008
Hematopoietic cell lineage 5.1 0.017
Colorectal cancer 5.0 0.018
Cytokine-cytokine receptor interaction 5.4 0.022
Bladder cancer 4.8 0.029
Endometrial cancer 4.9 0.046
Significant associations between the 100 most hypomethylated CpG sites in
the tumor relative to normal tissue, and KEGG cellular signal pathways (FDR
corrected p < 0.05). The 100 most hypermethylated CpG sites did not
significantly associate with any KEGG pathways
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epithelial cells [40]. Other infectious agents, such as the
Epstein-Barr virus, have also been implicated in the pro-
motion of DNA methylation in a subgroup of GC [39].
To evaluate the presence of H. pylori has not been the
aim of this study. Up-regulation of the IL-8 gene is a
general inflammatory marker and is also associated with
H. pylori-induced inflammation. The strong association
between expression of CLDN1 gene, methylation of
GFRA3 promoter and expression of IL-8 gene in tumor
tissue warrants further investigation in regards to the in-
fluence of H. pylori infection, but this is beyond the
scope of this study.
Our main findings, such as the hypermethylated
GFRA3 gene promoter and its possible prognostic role,
should be further studied in a larger cohort of patients
in the future.
Conclusion
In the present study, we demonstrated hypermethylation
of the GFRA3 promoter region in GC samples, and iden-
tified an inverse relationship between the degree of
GFRA3 hypermethylation and post-operative survival.
GFRA3 was also associated with CLDN1 gene expres-
sion, a potential prognostic factor demonstrated in a
previous study. The tumor and normal samples showed
distinct DNA methylation profiles, indicating that aber-
rant DNA methylation may be a distinct feature of GC.
Between the most aberrantly methylated gene promoters
and corresponding gene expression there was only mod-
est correlation, demonstrating that mechanisms other
than DNA methylation must account for many of the
changes in gene expression which occur in this disease.
Additional file
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